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Abstract
 
Zymosan is a 
 
 
 
-glucan– and mannan-rich particle that is widely used as a cellular activator for
examining the numerous responses effected by phagocytes. The macrophage mannose receptor
(MR) and complement receptor 3 (CR3) have historically been considered the major mac-
rophage lectins involved in the nonopsonic recognition of these yeast-derived particles. Using
specific carbohydrate inhibitors, we show that a 
 
 
 
-glucan receptor, but not the MR, is a pre-
dominant receptor involved in this process. Furthermore, nonopsonic zymosan binding was
unaffected by genetic CD11b deficiency or a blocking monoclonal antibody (mAb) against
CR3, demonstrating that CR3 was not the 
 
 
 
-glucan receptor mediating this activity. To address
the role of the recently described 
 
 
 
-glucan receptor, Dectin-1, we generated a novel anti–Dec-
tin-1 mAb, 2A11. Using this mAb, we show here that Dectin-1 was almost exclusively respon-
sible for the 
 
 
 
-glucan–dependent, nonopsonic recognition of zymosan by primary macro-
phages. These findings define Dectin-1 as the leukocyte 
 
 
 
-glucan receptor, first described over
50 years ago, and resolves the long-standing controversy regarding the identity of this impor-
tant molecule. Furthermore, these results identify Dectin-1 as a new target for examining the
immunomodulatory properties of 
 
 
 
-glucans for therapeutic drug design.
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Introduction
 
The ability of zymosan particles to stimulate cells of the
reticuloendothelial system was noted almost 50 yr ago (1)
and has led to their wide use in the investigation of many
phagocyte responses. Zymosan is a yeast-derived particle
composed principally of polysaccharides, of which 
 
 
 
-glu-
can, the active component mediating the cellular effects
(2), and mannan are the major constituents (3). In vivo ad-
ministration of zymosan, or purified soluble 
 
 
 
-glucans, has
a number of desirable effects on immune function, including
the ability to confer resistance to tumors and various infec-
tions, prompting interest in the development of 
 
 
 
-glucan–
based therapeutics (4, 5). Despite the significant therapeutic
implications, the molecular mechanism through which
these effects are mediated is not known.
Early studies, using carbohydrate inhibitors to block var-
ious leukocyte receptors, suggested that the cellular recog-
nition of unopsonized zymosan is mediated by the mannose
receptor and a 
 
 
 
-glucan receptor (6–8). The identity of the
 
 
 
-glucan receptor, which has been defined as a 
 
 
 
-glucan
inhibitable receptor for particulate activators of the alterna-
tive complement pathway (6), is controversial. The ability
of CR3 to recognize 
 
 
 
-glucans led to the proposal that this
receptor is the major 
 
 
 
-glucan receptor on leukocytes and
that it mediates all the immunomodulatory effects of these
carbohydrates, including the 
 
 
 
-glucan–dependent binding
of zymosan (4, 9–11). Conflicting evidence, however, in-
dicated that another receptor(s) mediates this activity (6,
12–14), and although we and others have identified addi-
tional receptors capable of recognizing 
 
 
 
-glucans (15–17),
their role in primary cells is unclear.
The main challenge in defining the contribution of these
various receptors to the recognition of 
 
 
 
-glucans has been
the lack of receptor-specific reagents. Here, using novel
and specific reagents, we have defined the receptors in-
volved in the nonopsonic recognition of zymosan and sol-
uble 
 
 
 
-glucans in primary macrophages. We have shown
that neither the MR nor CR3 are significantly involved,
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rather we demonstrate that the recently described Dectin-1
(17, 18) plays a major role in this process. These studies
suggest that Dectin-1 is the leukocyte 
 
 
 
-glucan receptor,
the identity of which has remained elusive since its first de-
scription over five decades ago.
 
Materials and Methods
 
Cells.
 
Thioglycollate (Tg)- or Biogel-elicited peritoneal and
bone marrow–derived macrophages (BMDMs) were isolated
from C57BL/6 mice by standard procedures and cultured over-
night in 24-well plates. Animals were kept and handled according
to institutional guidelines. C57BL/6 CD11b
 
 
 
/
 
 
 
 mice, generated
as described previously (19), were a gift from Dr. G. Hagger
(Glaxo-SmithKline, Stevenage, UK). Cells were maintained in
RPMI with 10% heat-inactivated FCS, 50 IU/ml penicillin G,
50 
 
 
 
g/ml streptomycin, and 2 mM glutamine (RPMI-medium);
except for BMDMs, which were cultured in RPMI-medium
supplemented with 15% (vol/vol) L-cell conditioned medium, as
a source of M-CSF (20). BMDMs were used 5 to 7 d after isola-
tion and culture.
 
Generation of mAbs against Dectin-1.
 
The mAb, 2A11, spe-
cific for Dectin-1, was generated by immunization of Fischer rats
with NIH3T3 cells transduced with full-length Dectin-1 (17) and
subsequent boosting with soluble recombinant, hemagglutinin
(HA)-tagged, Dectin-1. Recombinant Dectin-1 was harvested
from supernatants of the human 293T fibroblast cell line trans-
fected with pcDNA3.1 (Invitrogen) encoding an NH
 
2
 
-terminal
leader and HA-tag sequence fused to the extracellular portion of
Dectin-1 (amino acids 66 to 244). Splenic B cells from immu-
nized rats were then fused with the Y3 rat myeloma cell line (21),
according to standard protocols. Hybridoma supernatants were
initially screened by ELISA against the soluble recombinant form
of Dectin-1. The mAb 2A11 (IgG2b) was subsequently selected
based on its ability to recognize unfixed and unpermeabilized
cells transduced with Dectin-1, hence detecting an extracellular
epitope. Other antibodies used in this study were 5C6 (anti-
CR3; reference 22) and a rat IgG2b isotype control.
 
Flow Cytometry and Immunoprecipitation.
 
Flow cytometry was
performed according to conventional protocols. Cells were ex-
amined by three-color FACS
 
®
 
 analysis using biotin-conjugated
2A11, phycoerythrin-conjugated F4/80 (Serotec) and FITC-
conjugated 5C6. Biotin- or FITC-conjugated rat IgG2b were
used as isotype controls. Allophycocyanin-conjugated streptavi-
din (BD Biosciences) was used to detect the biotin conjugates.
For immunoprecipitation, soluble recombinant HA-tagged
Dectin-1 was incubated with 2A11 or rat IgG2b isotype control
and then captured with sheep anti–rat IgG magnetic beads (Dynal).
Western blotting, after SDS-PAGE, was performed according to
standard protocols. The mouse mAb HA11 (anti-HA; Covance)
and donkey anti–mouse IgG horseradish peroxidase conjugate
(Jackson ImmunoResearch Laboratories) were used to detect the
HA-tagged protein using the ECL chemiluminescence substrate
(Amersham Biosciences).
 
Fluorescent Zymosan Binding Assays.
 
The fluorescence-based
binding assays using FITC-labeled zymosan were performed as
described (17, 23), except that in all experiments the cells were
maintained at 4
 
 
 
C, to prevent the local release of opsonins, in-
cluding complement (24, 25). In brief, macrophages were plated
at 2.5 
 
 
 
 10
 
5
 
 cells/well in 24-well plates in RPMI-medium over-
night. The cells were cooled to 4
 
 
 
C and washed three times with
prechilled culture medium. Zymosan-FITC (Molecular Probes)
was added to the cells at a ratio of 25 particles/cell for 1 h on ice.
After incubation with the carbohydrate or antibody inhibitors,
described below, unbound zymosan was removed by extensive
washing with medium and cells were then lysed with 3% Triton
X-100. FITC in lysates was quantified using a Titretek Fluoro-
skan II (Labsystems Group Ltd.). Unless otherwise stated the
amount of fluorescence was normalized to the uninhibited con-
trol and expressed at percent relative fluorescence. All experi-
ments were repeated at least three times.
To obtain opsonized particles, FITC-labeled zymosan was in-
cubated with neat normal mouse serum for 30 min at 37
 
 
 
C and
then washed extensively in RPMI-medium before use. Binding
of opsonized FITC-labeled zymosan to cells was performed as for
the unopsonized zymosan, described above.
 
Carbohydrate and Antibody Inhibition Experiments.
 
All carbohy-
drates were obtained from Sigma-Aldrich, except for glucan
phosphate, a structurally defined and biologically active glucan,
which was prepared as described (26). To perform inhibition ex-
periments, carbohydrates (100 
 
 
 
g/ml) were added to washed
cells for 20 min before the addition of FITC-labeled zymosan.
The antibody inhibition experiments were performed simi-
larly, except that the cells were incubated with the mAbs in PBS
for 1 h, and then washed extensively before the determination of
zymosan binding.
To determine the role of Dectin-1 in the direct recognition of
soluble 
 
 
 
-glucans, carbohydrates were added to the cells at 100
 
 
 
g/ml for 1 h at 4
 
 
 
C, after which the cells were washed and
stained in situ. The cells were then detached using a cell scraper
and analyzed by flow cytometry, as described above. To internal-
ize the receptor, the washed cells were warmed at 37
 
 
 
C for 7 min
and then immediately returned to 4
 
 
 
C.
 
Results and Discussion
 
The Recognition of Unopsonized Zymosan Is Predominantly
Mediated by a 
 
 
 
-Glucan Receptor.
 
To investigate the role
of various receptors in recognition of zymosan, we exam-
ined the ability of receptor-specific carbohydrates to inhibit
the binding of FITC-labeled zymosan to a variety of pri-
mary macrophages in the absence of complement. Lami-
Figure 1. A  -glucan receptor is a major receptor for unopsonized zy-
mosan. The  -glucan, laminarin, specifically inhibits the recognition of
unopsonized FITC-labeled zymosan by BMDM (white bars), Tg-
(striped bars), and Biogel-elicited macrophages (black bars). The addition
of carbohydrates which block the mannose receptor (mannan) and the
lectin domain of CR3 (methyl glucoside) had no effect on zymosan bind-
ing. The data shown have been normalized to the uninhibited control
and expressed as percent relative fluorescence. 
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narin, a soluble fungal derived 
 
 
 
-glucan widely used to de-
fine leukocyte 
 
 
 
-glucan receptor activity (6, 8, 10), exerted
a strong inhibitory effect on the recognition of unop-
sonized zymosan (Fig. 1). This is in accordance with early
studies, which demonstrated a role for a 
 
 
 
-glucan receptor
in the nonopsonic recognition of zymosan (6, 14). In con-
trast, the addition of mannan, also previously shown to in-
hibit the recognition of unopsonized zymosan (7, 8), had
no effect. Our results support other studies, which indi-
cated that inhibition of zymosan binding by mannan was a
result of contamination of the yeast mannan preparations
with 
 
 
 
-glucans (6, 14). This suggests that the mannose re-
ceptor does not play a significant role in this process. Sur-
prisingly, methyl glucoside, an inhibitor of the CD11b lec-
tin binding domain (10), had no effect, even at 40-fold
molar excess compared with laminarin. This lack of inhibi-
tion was not due to the experimental conditions, as the
ability of the lectin domain of CR3 to bind carbohydrate
ligands at 4
 
 
 
C has been previously shown (10). This sug-
gested that CR3 may not be involved in the recognition of
unopsonized zymosan.
 
CR3 Is Not Involved in the Nonopsonic Recognition of Zy-
mosan by Macrophages.
 
To confirm the lack of involve-
ment of CR3, we next examined the ability of macro-
phages from CD11b
 
 
 
/
 
 
 
 mice, which lack functional CR3
(19), to recognize zymosan. CR3-deficient and wild-type
Figure 2. CR3 is not a receptor for unopsonized
zymosan on macrophages. (A) The  -glucan depen-
dent recognition of unopsonized zymosan is unaf-
fected in CR3-deficient (CD11b / ) BMDM. (B)
CR3 deficiency does affect the binding of serum
opsonized FITC-labeled zymosan, although recog-
nition of opsonized zymosan in both types of mac-
rophage retains a  -glucan–dependent component.
The data are shown as the directly measured fluores-
cence units and have not been normalized, so as to
allow a direct comparison between the macro-
phages. Note the difference in scale between the pan-
els (A and B). The data shown are the average of trip-
licates and error bars indicate the standard deviation.
Figure 3. The mAb 2A11 recognizes Dectin-1
and detects its expression on the surface of primary
macrophages. (A) The mAb 2A11, but not an
IgG2b control mAb, recognizes Dectin-1, and can
specifically immunoprecipitate soluble recombinant
hemagglutinin (HA)-tagged Dectin-1. (B) The mAb
2A11 stains Dectin-1 transductants (shaded histo-
gram), but not nontransduced cells (unshaded histo-
gram), by flow cytometry. (C) 2A11 detects Dectin-1
expression on the surface of freshly isolated F4/
80 CR3  Tg macrophages. The gate shown in the
left panel denotes the population examined in the
right panels. (D) Dectin-1 is expressed at a similar
level on the surface of both wild-type and CD11b / 
bone marrow–derived macrophages. 
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BMDMs bound unopsonized zymosan equally well, and in
a 
 
 
 
-glucan–dependent fashion (Fig. 2 A). As before, bind-
ing of unopsonized zymosan was not inhibited by mannan
or methyl glucoside.
Opsonized zymosan showed markedly enhanced binding
to the wild-type cells but not to CD11b
 
 
 
/
 
  
 
cells, as ex-
pected, consistent with the absence of CR3 from these cells
(Fig. 2 B). Furthermore, laminarin was still able to inhibit
the binding of opsonized particles to wild-type cells par-
tially. This suggests that 
 
 
 
-glucan recognition can also con-
tribute to the binding of opsonized yeast particles, explain-
 
ing previous observations reporting the lack of specificity of
C3-opsonized zymosan for CR3 in macrophages (27).
These results therefore demonstrate that a macrophage
 
 
 
-glucan receptor, distinct from CR3, was a major recep-
tor involved in the nonopsonic recognition of zymosan and
that this receptor also contributed to the recognition of op-
sonized zymosan particles.
 
Dectin-1 Is Expressed on the Surface of Macrophages.
 
We
recently identified Dectin-1 as a receptor which could bind
unopsonized zymosan in transduced murine fibroblasts
through a binding site which was distinct from that for T
cell recognition (17, 18, 23). Although Dectin-1 was ini-
tially suggested to be a dendritic cell–specific receptor (18),
we have previously shown that Dectin-1 mRNA was ex-
pressed in other cell types, including primary macrophages
and PMN (17, 23). To explore the role of this receptor in
primary macrophages, we generated a novel Dectin-1–spe-
cific monoclonal antibody, 2A11 (IgG2b), as described in
Materials and Methods. The specificity of this mAb was
confirmed by its ability to immunoprecipitate soluble re-
combinant HA-tagged Dectin-1 (Fig. 3 A). Furthermore,
2A11 specifically stained the surface of live Dectin-1 trans-
duced NIH3T3 fibroblasts, indicating that it recognized an
extracellular epitope (Fig. 3 B).
As the epitope recognized by the mAb 2A11 was sensi-
tive to fixation (unpublished data), we examined the ex-
pression of Dectin-1 on the surface of live primary mac-
rophages by flow cytometry. Consistent with our previous
data (17, 23), we detected Dectin-1 protein on the surface
of freshly isolated Tg-elicited peritoneal (Fig. 3 C), Biogel-
elicited peritoneal (unpublished data), and on BMDM (Fig.
3 D). Dectin-1 was found to be expressed on the surface of
all macrophage populations tested as well as on monocytes,
dendritic cells, and neutrophils (unpublished data), demon-
strating that Dectin-1 is not restricted to cells of the den-
Figure 4. Dectin-1 is a major macrophage receptor for unopsonized
zymosan. (A) 2A11 (anti-Dectin-1), but not 5C6 (anti-CR3), specifically
inhibits the recognition of unopsonized FITC-labeled zymosan by Tg
macrophages. The level of inhibition with 2A11 is similar to that ob-
tained with the exogenous  -glucan, glucan phosphate (GluP), or lami-
narin (unpublished data). Samples have been normalized to their respec-
tive controls, indicated by similar shading, and the data shown are from a
representative experiment and are the average of triplicates with error bars
indicating the standard deviation. (B) Both 2A11 and 5C6 can inhibit the
binding of opsonized FITC-labeled zymosan, although the absolute val-
ues vary depending on the level of opsonization. The simultaneous addi-
tion of both antibodies, however, always had an additive inhibitory effect.
To demonstrate the variation in the level of opsonization and its effects
on the inhibition obtained with the antibodies, the data shown are the av-
erage of the means of triplicates from three independent experiments, and
the error bars indicate the standard error of the mean.
Figure 5. Soluble  -glucans block the ability of 2A11 to detect Dec-
tin-1 on Tg-elicited peritoneal macrophages. Flow cytometric analysis of
the surface levels of Dectin-1 and CR3 before and after the addition of
glucan phosphate (GluP) or laminarin (Lam), with or without brief
warming at 37 C to induce receptor internalization. Cells were stained
with isotype-control (IgG2b) or receptor-specific mAbs, in the presence
and absence of the exogenous glucans, as indicated above the panels. No
difference in 2A11 staining was observed when the cells were warmed
without glucan phosphate or laminarin (unpublished data). 
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dritic cell lineage. Similar levels of Dectin-1 were also ob-
served on the surface of macrophages from CR3-deficient
and wild-type mice (Fig. 3 D). This observation is compat-
ible with a role for Dectin-1 in the nonopsonic, 
 
 
 
-glucan–
dependent, recognition of zymosan by CD11b-deficient
cells, see below.
 
Dectin-1 Plays a Major Role in the 
 
 
 
-Glucan–dependent Rec-
ognition of Zymosan by Macrophages.
 
Having shown that
nonopsonic zymosan recognition by primary macrophages
was mediated by a 
 
 
 
-glucan inhibitable receptor, which
was different to CR3, we next examined the role of Dec-
tin-1 in this process. We observed that the mAb, 2A11, in-
hibited the binding of unopsonized zymosan to a level
comparable with the inhibition obtained with the exoge-
nous 
 
 
 
-glucans, glucan phosphate or laminarin, indicating
that this mAb bound at or near the 
 
 
 
-glucan binding site
(Fig. 4 A). 2A11 could also inhibit the binding of zymosan
to NIH3T3 transductants expressing Dectin-1 (unpub-
lished data). The mAb, 5C6 (22), which blocks the lectin
activity of CR3 (9), had no effect on zymosan binding,
supporting our previous observations, described above.
Similar results were obtained when macrophages were
plated on dishes coated with receptor specific antibodies, a
process shown to sequester receptors from the upper,
ligand-interacting, cell surface (28; and unpublished data).
We also examined the effects of these antibodies on the
recognition of opsonized zymosan by macrophages (Fig. 4
B). Although we found that the individual levels of inhibi-
tion by 2A11 and 5C6 depended on the degree of op-
sonization, the simultaneous addition of both antibodies
consistently had a additive effect in inhibiting the binding
of opsonized zymosan. The levels of inhibition obtained
with 5C6 were, however, similar to those previously ob-
tained with other anti-CR3 antibodies (9). Furthermore,
the inhibition obtained with 2A11 always correlated with
that obtained with exogenously added 
 
 
 
-glucans, indicating
that Dectin-1 was mediating the 
 
 
 
-glucan–dependent rec-
ognition of opsonized zymosan, as discussed above. Thus,
we conclude that Dectin-1 is a major receptor for unop-
sonized zymosan on macrophages, and that it can also con-
tribute to the recognition of opsonized zymosan particles.
As Dectin-1 acts as a pattern recognition receptor for a
variety of 
 
 
 
-1,3 and/or 
 
 
 
-1,6 glucan linked carbohydrates
in transduced murine fibroblasts (17), we extended our ob-
servations to determine if binding of soluble 
 
 
 
-glucans to
primary cells was also mediated by this receptor. The solu-
ble 
 
 
 
-glucans, glucan phosphate and laminarin, shown to
be the best 
 
 
 
-glucan inhibitors of Dectin-1 binding to zy-
mosan (17, 23), masked the 2A11 epitope on macrophages
(Fig. 5). This indicates that Dectin-1 was involved in the
recognition of these polysaccharides. Warming the cells
briefly further reduced the detection of this receptor (Fig.
5), consistent with the observation that 
 
 
 
-glucans are inter-
nalized after receptor binding (26). No change in the level
of surface expressed CR3 was observed, even after warm-
ing (Fig. 5). Taken together, these results suggest that Dec-
tin-1 is a major receptor for both unopsonized-particulate
and soluble 
 
 
 
-glucans on macrophages.
Our results establish a predominant role for Dectin-1 in
the innate recognition of 
 
 
 
-glucans. We have demon-
strated that the 
 
 
 
-glucan receptor, Dectin-1, is expressed
on primary macrophages and that it is a major receptor for
unopsonized zymosan. These conclusions, which contra-
dict previous established dogma, are strengthened by the
use in our experiments of structurally defined, pure 
 
 
 
-glu-
cans, receptor-specific reagents, and the care taken in con-
trolling for the contribution of opsonic factors released
from the cells under study (24, 25).
The identification of Dectin-1 as a major leukocyte
 
 
 
-glucan receptor defines the fundamental mechanism of
 
 
 
-glucan recognition by macrophages that has remained
elusive since its first description over five decades ago. As
soluble 
 
 -glucans, which can be detected in the plasma of
patients with invasive fungal infections (29), do not have
the capacity to activate complement (30), the nonopsonic
receptor Dectin-1 could play a central role in the innate
recognition of these carbohydrate polymers and may be a
therapeutic target for novel drug design.
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